Virtual Seminar: Von Willebrand Factor Inhibition in Acute Ischemic Stroke: From Target to Trial
Shahid Nimjee, M.D., Ph.D.
Associate Professor of Neurological Surgery
Co-Director, Stroke Center
Wexner Medical Center
The Ohio State University
Virtual Timothy A. Johnson Medical Scholar Lecture: Von Willebrand Factor Inhibition in Acute Ischemic Stroke: From Target to Trial
About this Seminar
Acute ischemic stroke (AIS) is the leading cause of combined morbidity and mortality worldwide. Recombinant tissue plasminogen activator (rtPA) is the only approved pharmacological treatment for AIS but is limited to treating patients within 4.5 hours of stroke onset because of the risk of intracranial hemorrhage. Moreover, it is ineffective in treating large vessel occlusion (LVO) stroke. Endovascular mechanical thrombectomy (MT) effectively recanalizes LVO stroke but it is limited to highly-specialized hospitals, leaving the vast majority without timely acute treatment. Dr. Nimjee hypothesizes that targeted von Willebrand Factor (VWF) inhibition by BB-031 will recanalize arterial thrombosis in a canine model of LVO stroke. Utilizing a canine embolic middle cerebral artery occlusion (eMCAO) model of LVO stroke, his lab assessed BB-031 administration at 0.5mg/kg 6 hours after stroke induction on platelet activity by PFA-100, vessel recanalization by digital subtraction angiography, infarct volume and intracranial hemorrhage by MRI. BB-031 administration after 6 hours of LVO stroke resulted complete inhibition of platelet activity. Moreover, it recanalized MCAO to >TICI 2A in 62.5% and >TICI 2B in 50% of canines (n=8). Negative control group demonstrated no revascularization (n=7). Recanalization resulted in reduced infarct volume compared to negative control (p<0.05). BB-031 administration induced no intracranial hemorrhage. VWF inhibition by BB-031 completely inhibited platelet activity, and effectively recanalizes LVO when administered 6 hours after stroke onset. Recanalization resulted in reduced infarct volume, without any incidence of intracranial hemorrhage. Targeted therapy against VWF represents a robust yet safe approach to treat AIS.
This is a free event hosted by the Fralin Biomedical Research Institute and the Virginia Tech Carilion School of Medicine. The Timothy A. Johnson Medical Scholar Lecture Series hosts clinician scientists who are exploring frontiers of medicine. These lectures are principally intended for Virginia Tech Carilion School of Medicine students and Virginia Tech students in the Translational Biology, Medicine, and Health graduate program. Virginia Tech and Carilion Clinic faculty, staff, and students may also attend.
You May Also Be Interested In...
Home ItemIn Person Seminar: Win to Fight and Lose to Flight: Innate Yet Flexible Aggression Circuit , home
March 24, 2023, 11 a.m. | Dayu Lin, Ph.D., Professor, Department of Psychiatry, Grossman School of Medicine, New York University | Pioneers in Biomedical Research Seminar Series | Co-Sponsored by the Fralin Biomedical Research Institute Center for Neurobiology Research
Home ItemSeminar: Signaling and Metabolic Control of Nucleotide Metabolism in Cancer , home
March 27, 2023, 11 a.m. | Eunus S. Ali, Ph.D., Postdoctoral Associate, Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University | Seminar
Home ItemIn Person Seminar: Quantifying Diverse Research Representation , home
March 31, 2023, 11:00 a.m. | Jonathan Jackson, Ph.D., Executive Director, Community Access, Recruitment, and Engagement (CARE) Research Center, Harvard University and Massachusetts General Hospital | Pioneers in Biomedical Research Seminar Series | Co-Sponsored by the Fralin Biomedical Research Institute Center for Human Neuroscience Research
Home ItemIn Person Lecture: Synaptic Injury: A Link to the Past , home
March 31, 2023, 1 p.m. | Terrance Kummer, M.D., Ph.D., Associate Professor of Neurology, Washington University School of Medicine in St. Louis | Timothy A. Johnson Medical Scholar Lecture Series
Home ItemSeminar: Understanding Cancer: From Development to Therapy , home
April 5, 2023, 11 a.m. | Biplab Dasgupta, M.S., Ph.D., MBA, Professor of Pediatrics, Division of Oncology, Cincinnati Children's Hospital | Seminar
Home ItemIn Person Seminar: Brain Dynamics and Flexible Behaviors , home
April 14, 2023, 11:00 am. | Lucina Q. Uddin, Ph.D., Professor in Residence, Department of Psychiatry and Biobehavioral Science, University of California, Los Angeles | Pioneers in Biomedical Research Seminar Series | Co-Sponsored by the Fralin Biomedical Research Institute Addiction Recovery Research Center and Center for Health Behaviors Research